Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten
rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS …

Simple Summary Aberrant DNA methylation is associated with multiple malignancies,
including lung cancer. Differences in methylation patterns have been observed across lung …

Objectives After decades of unsuccessful efforts in inhibiting KRAS, promising clinical data
targeting the mutation subtype G12C emerge. Since little is known about outcome with …

KRAS mutations are one of the most frequent oncogenic mutations of all human cancers,
being more prevalent in pancreatic, colorectal, and lung cancers. Intensive efforts have been …

Background The efficacy of atezolizumab (A) and/or bevacizumab (B) with
carboplatin/paclitaxel (CP) chemotherapy was explored in the phase III, randomized …

KRAS mutations are one of the most prevalent oncogenic alterations in cancer. Until
recently, drug development targeting KRAS did not convey clinical benefits to patients …

Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

Objectives Effective therapy for non–small-cell lung cancer (NSCLC) depends on
morphological and genomic classification, with comprehensive screening for guideline …

Objectives To evaluate the impact of smoking history on the clinical benefit of
immunotherapy in patients with non-small cell lung cancer (NSCLC). Methods Twenty-three …

Statins, known as HMG-CoA reductase (HMGCR) inhibitors, have primarily been utilized for
metabolic and angiographic medical applications because of their cholesterol-lowering …